Total
0
Shares
Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu
CEO and MD, Dr Oludare Odumosu
Source: Zelira Therapeutics
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Zelira Therapeutics (ZLD) raises US$5 million (around A$6.68) from US family office fund, Quincy Street Capital
  • Quincy Street has now become a substantial shareholder in Zelira with a 6.3 per cent stake
  • Funds from the raise will be used to speed up the company’s growth initiatives
  • Zelira is up 20.5 per cent and is trading at 4.7 cents per share at 12:52 pm AEDT

Zelira Therapeutics (ZLD) has raised US$5 million (around A$6.68) from US family office fund, Quincy Street Capital.

The funding included US$3.5 million (about A$4.68 million) via a placement, nearly 40 million unlisted options and US$1.5 million (approx. A$2 million) via an equity investment in Ilera Derm.

Under the placement, Quincy purchased around 79.9 million shares at six cents each.

Following this funding, Quincy Street has become a substantial shareholder in Zelira with a 6.3 per cent stake.

Funds from the raise will be used to speed up the company’s growth initiatives. This includes clinical development and ongoing trials in Australia and US, additional licensing for Zelira Rx product and commercialisation of RAF FIVE.

Recently, the company launched its first product line, RAF FIVE, through its dermatology subsidiary, Ilera Derm.

The product line includes a mix of acne treatment and sunscreen, and known skin-boosting ingredients such as peptides and hyaluronic acid.

Zelira’s Founder and Chairman, Osagie Imasogie, is pleased to welcome Quincy Street as a new shareholder.

“This capital raise, undertaken at a substantial premium to the current trading price, is a strong signal of the fundamental value this sophisticated and experienced investor sees in our scientifically based cannabinoid products that are already in market and coming to
market, as well as our growing biopharmaceutical portfolio,” he said.

“We have an ambitious product development and sales growth strategy that we are executing on. The funds raised have not only introduced a new US-based fund onto Zelira’s register, but more importantly, provide us with the capital to more aggressively roll out our growth strategy with a target of reaching financial breakeven by the end of next calendar year.”

Zelira was up 20.5 per cent and is trading at 4.7 cents per share at 12:52 pm AEDT.

ZLD by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert

" Rhythm Biosciences (ASX:RHY) achieves CE Mark for ColoSTAT

Cancer diagnostic technology company Rhythm Biosciences (RHY) has achieved CE Mark certification for ColoSTAT.
EMVision Medical Devices (ASX:EMV) - CEO, Ron Weinberger

" EMVision Medical Devices (ASX:EMV) reports more strong results

Medical device maker EMVision (EMV) is spiking on the ASX today after releasing further results from a pilot clinical trial of its brain
ECS Botanics (ASX:ECS) - Managing Director and Founder, Alex Keach

" ECS Botanics’ (ASX:ECS) subsidiary buds $4.9m supply agreement

ECS Botanics’ (ECS) subsidiary has secured a $4.9 million agreement to supply resin to Australian cannabis company, Cannvalate.
Arovella Therapeutics (ASX:ALA) - CEO and Managing Director, Dr Michael Baker

" Arovella Therapeutics (ASX:ALA) receives $524,000 R&D tax refund

Arovella Therapeutics (ALA) has received a refund from the Australian Taxation Office (ATO) of just over $524,000 for the financial year.